New drug treatment Kyprolis® (carfilzomib) for relapsed multiple myeloma launches in the UK

In a clinical trial, relapsed patients treated with carfilzomib in combination with lenalidomide and dexamethasone lived 8.7 months longer without disease progression compared with lenalidomide and dexamethasone alone
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Clinical trials Practical therapeutics Oncology Patient care Research ASPIRE study carfilzomib ENDEAVOR study Latest News multiple myeloma rare blood cancer Source Type: news